可植入胫神经调控疗法改善急迫性尿失禁症状:TITAN 2关键研究
TITAN 2是一项前瞻性、多中心、单臂IDE研究,评估Medtronic可植入胫神经调控系统治疗急迫性尿失禁(UUI)的安全性和有效性。共植入126例受试者,6个月时59%达到UUI发作≥50%减少(95%CI 49%-67%,P<.0001),12个月为61%;
要点
- 6个月时59%受试者UUI发作减少≥50%,12个月为61%。
- UUI发作、排尿次数和紧迫感知评分在6个月显著改善并维持至12个月。
核心结论
- TITAN 2研究达到主要和所有次要终点,显示UUI、尿频和紧迫症状的统计学显著改善。
- 临床获益和良好安全性维持至12个月。
研究设计与样本
- 前瞻性、多中心、单臂IDE研究,纳入伴UUI的膀胱过度活动症受试者。
- 共植入126例受试者,95%为女性,平均年龄63±14岁,BMI 35±9 kg/m2。
- 主要终点为6个月时UUI发作/天减少≥50%的受试者百分比。
主要发现
- 6个月时59%受试者达到UUI发作/天减少≥50%(95%CI 49%-67%,P<.0001)。
- 12个月时61%受试者达到UUI发作/天减少≥50%。
- 6个月时UUI发作/天、排尿次数/天(尿频受试者)和紧迫感知评分较基线变化有统计学显著性,且改善维持至12个月。
关键数值与推荐
- 主要终点:6个月时UUI发作/天减少≥50%的受试者比例为59%(95%CI 49%-67%,P<.0001)。
- 12个月时UUI发作/天减少≥50%的受试者比例为61%。
临床怎么用
- 可植入胫神经调控系统可作为UUI的微创治疗选择,12个月内可维持症状改善。
局限性
- 单臂研究设计,缺乏对照。
- 随访报告至12个月,长期数据未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The Medtronic implantable tibial neuromodulation system is a leadless, rechargeable, minimally invasive option intended to treat the symptoms of urge urinary incontinence (UUI), a common condition that significantly impairs quality of life. TITAN 2 is a pivotal study evaluating safety and effectiveness of the Medtronic implantable tibial neuromodulation system. The results through 12 months are reported. MATERIALS AND METHODS: This prospective, multicenter, single-arm investigational device exemption study enrolled eligible overactive bladder subjects with UUI. The primary end point was the percentage of subjects who had ≥ 50% reduction in UUI episodes/day after 6 months. Safety was characterized as the rate of adverse device effects (ADEs). Data are reported as mean ± SD or with 95% CIs. RESULTS: Of 126 implanted subjects, 95% were female, the mean age was 63 ± 14 years, and BMI was 35 ± 9 kg/m2. The primary objective was met with 59% of subjects achieving ≥ 50% improvement in UUI episodes/day (95% CI: 49%-67%, P < .0001) at 6 months; at 12 months, 61% had ≥ 50% improvement. Change from baseline was statistically significant at 6 months for UUI episodes/day, voids/day (in urinary frequency subjects), and Urgency Perception Score, with improvements in all 3 symptoms maintained through 12 months. Twenty percent of subjects experienced ADEs through 12 months; 1 ADE was serious and was recovered/resolved. CONCLUSIONS: TITAN 2 met the primary and all secondary objectives by showing a statistically significant improvement of UUI, urinary frequency, and urgency symptoms. Clinical benefits and a favorable safety profile were maintained through 12 months.
引用
- Lee U, Xavier K, Carey J, et al. Implantable Tibial Neuromodulation Therapy Improves Symptoms of Urge Urinary Incontinence From the TITAN 2 Pivotal Study. J Urol. 2026. PMID: 41587348. doi:10.1097/JU.0000000000004958
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。